4//SEC Filing
Elvig Mark F 4
Accession 0001000229-18-000012
CIK 0001000229other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 6:07 PM ET
Size
9.0 KB
Accession
0001000229-18-000012
Insider Transaction Report
Form 4
Elvig Mark F
VP, Counsel & Secretary
Transactions
- Tax Payment
Common Shares
2017-12-29$109.55/sh−821$89,941→ 22,404 total - Exercise/Conversion
Common Shares
2017-12-29+3,000→ 23,225 total - Exercise/Conversion
Performance Shares
2017-12-29−3,000→ 0 totalExercise: $0.00→ Common Shares (3,000 underlying)
Holdings
- 2,568(indirect: By 401(k))
Common Shares
Footnotes (1)
- [F1]The shares vesting were awarded as restricted performance shares in February 2015 as reported in the Form 4 filing on February 17, 2015. This filing states that 100% of the restricted performance shares will vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. The performance criteria and all requirements for vesting have been met and thus the shares fully vested on December 29, 2017, at the conclusion of the performance period.
Documents
Issuer
CORE LABORATORIES N V
CIK 0001000229
Entity typeother
Related Parties
1- filerCIK 0001435153
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 6:07 PM ET
- Size
- 9.0 KB